Italia markets closed

Evotec SE (0IRF.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
25,91+0,48 (+1,88%)
Alla chiusura: 05:18PM GMT

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Settore/i
Settore
Impiegati a tempo pieno5.086

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Mario Polywka DPHIL, Ph.D.Interim CEO, Member of the Management Board & Member of the Supervisory BoardN/DN/D1963
Dr. Werner Lanthaler M.B.A., MPA, Ph.D.Member of Management Board1,32MN/D1968
Dr. Cord Dohrmann Ph.D.Chief Scientific Officer & Member of Management Board804kN/D1964
Dr. Craig Johnstone Ph.D.COO & Member of Management Board712kN/D1970
Dr. Matthias Evers Ph.D.Chief Business Officer & Member of Management Board636kN/D1973
Ms. Laetitia RouxelCFO & Member of Management BoardN/DN/D1974
Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingN/DN/DN/D
Mr. Volker BraunSenior VP and Global Head of Investor Relations & ESGN/DN/DN/D
Dr. Christian DargelEVP Global Head of Legal & ComplianceN/DN/DN/D
Gabriele HansenSenior VP & Head of Global Corporate Communications & MarketingN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Evotec SE al 28 febbraio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.